Borderline tuberculoid leprosy in dark-skinned individuals often presents with well-defined, hypopigmented patches that may be difficult to distinguish due to minimal contrast with the surrounding skin. These patches are associated with nerve involvement, leading to sensory loss and muscle weakness in affected areas. Treatment typically involves multidrug therapy (MDT) with dapsone, rifampicin, and sometimes clofazimine, alongside managing nerve damage to prevent disability.